Evogene (NASDAQ: EVGN) reported Q2 EPS of ($0.13), $0.15 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $325 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.